SLC16A2

Across TCGA pan-cancer cohorts, SLC16A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC16A2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SLC16A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC16A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BRCA, UCS, and SARC are the cancer types where SLC16A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.776	0.963	<.001	38	view →
UCS	DFS	Median	All	0.151	0.529	.048	6	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	DFS	Median	II,III,IV	0.870	0.480	.047	2	view →
SKCM	OS	Median	All	0.834	0.311	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC16A2–BRCA (OS)

Open the BRCA breakdown →